pulmonx
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
700 Chesapeake Dr, Redwood City, Califor...Phone Number
(650) 364-0400Website
www.pulmonx.comRevenue
$87.4 MillionStock Symbol
LUNGIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About pulmonx
Pulmonx Corporation is a commercial-stage medical technology company focused on developing and commercializing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's flagship product, the Zephyr® Endobronchial Valve, is an FDA-approved implant designed to reduce lung hyperinflation by collapsing diseased portions of the lung, thereby improving breathing and quality of life for patients. Pulmonx also offers diagnostic and planning tools such as the Chartis® Pulmonary Assessment System and the StratX®/LungTraX® platforms, which help identify appropriate candidates for treatment through advanced lung imaging and functional assessment. With over 40,000 patients treated globally, Pulmonx is a leader in the interventional pulmonology space.Explore more
pulmonx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is pulmonx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at pulmonx
Earning: See what the market has to say on pulmonx recently announced quarterly report
Product Launch: Get notified when pulmonx launches new products
Check out if pulmonx is spiking on competitors!
pulmonx, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once pulmonx has new funding data
Check if pulmonx has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if pulmonx had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined pulmonx as Masked Content
Find 3 more new buyers
Compare Similar Companies to pulmonx
Compare insights from companies similar to pulmonx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
pulmonx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
pulmonx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about pulmonx.
pulmonx financials insights
Gather financial insights about pulmonx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series A
$7.1M
2007
Series B
$20M
2010
Series C
$32M
2012
Series D
$10M
2014
Private Equity
$10M
Debt
$20M
2015
Private Equity
$50M
2020
Multiple Rounds
$272M
pulmonx Tech Stack
A closer look at the technologies used by pulmonx
See more technologies
Most Recent Scoops
Earnings
pulmonx has reported a gross margin of 78% over the last couple of quarters, benefiting from production efficiencies, supply chain cost reductions, and a favorable distributor mix, while noting that gross margins on a normalized basis are expected to be at or above approximately 75%.
Earnings, Logistics / Supply Chain, Finance
Earnings
pulmonx has reiterated its revenue guidance of $90 to $92 million, citing progress in its commercial turnaround, specifically in the US market.
Earnings, Finance
Earnings
pulmonx has reported cash operating expenses down approximately 11% year over year in Q2, following a cost restructuring initiative implemented at the start of the year that reduced ongoing recurring costs by approximately 10%, with the OpEx guidance change primarily reflecting a reduction in non-cash stock-based compensation expense.
Earnings, Spending/Investment, Finance, Financial Operations
Earnings
pulmonx has reported U.S. revenue of $14.2 million for Q2 2026, a 4% decrease from $14.7 million in the same period of the prior year, and a 7% sequential increase from Q1 2026. pulmonx added 12 new U.S. treating centers during the quarter.
Earnings, Finance, Revenue Operations
Earnings
pulmonx News & Media
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q2 2026 Earnings Call July 29, 2026 4:30 PM EDTCompany ParticipantsGlendon French - CEO, President & DirectorDerrick Sung -...Pulmonx Q2 Earnings Call Highlights
Pulmonx (NASDAQ:LUNG) reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China. Revenue for the quarterPulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding pulmonx
Sign Up For FreeTo access detailed company insights
Pulmonx Corporation is a commercial-stage medical technology company focused on developing and commercializing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's flagship product, the Zephyr® Endobronchial Valve, is an FDA-approved implant designed to reduce lung hyperinflation... Read More
